These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

405 related items for PubMed ID: 16204619

  • 1. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
    Gordon JR, Li F, Zhang X, Wang W, Zhao X, Nayyar A.
    J Leukoc Biol; 2005 Dec; 78(6):1265-72. PubMed ID: 16204619
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels.
    Zhao X, Town JR, Li F, Zhang X, Cockcroft DW, Gordon JR.
    J Immunol; 2009 Mar 01; 182(5):3213-22. PubMed ID: 19234219
    [Abstract] [Full Text] [Related]

  • 5. CXCL8((3-73))K11R/G31P antagonizes the neutrophil chemoattractants present in pasteurellosis and mastitis lesions and abrogates neutrophil influx into intradermal endotoxin challenge sites in vivo.
    Li F, Zhang X, Mizzi C, Gordon JR.
    Vet Immunol Immunopathol; 2002 Nov 01; 90(1-2):65-77. PubMed ID: 12406656
    [Abstract] [Full Text] [Related]

  • 6. Amelioration of pathology by ELR-CXC chemokine antagonism in a swine model of airway endotoxin exposure.
    Gordon JR, Zhang X, Li F, Nayyar A, Town J, Zhao X.
    J Agromedicine; 2009 Nov 01; 14(2):235-41. PubMed ID: 19437283
    [Abstract] [Full Text] [Related]

  • 7. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
    Khan MN, Wang B, Wei J, Zhang Y, Li Q, Luan X, Cheng JW, Gordon JR, Li F, Liu H.
    Oncotarget; 2015 Aug 28; 6(25):21315-27. PubMed ID: 26087179
    [Abstract] [Full Text] [Related]

  • 8. Porcine CXCR1/2 antagonist CXCL8(3-72)G31P inhibits lung inflammation in LPS-challenged mice.
    Wang X, Li Y, Li L, Jiao Z, Liu X, Cheng G, Gu C, Hu X, Zhang W.
    Sci Rep; 2020 Jan 27; 10(1):1210. PubMed ID: 31988368
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Blockade of neutrophil responses in aspiration pneumonia via ELR-CXC chemokine antagonism does not predispose to airway bacterial outgrowth.
    Zhao X, Town JR, Li F, Li W, Zhang X, Gordon JR.
    Pulm Pharmacol Ther; 2010 Feb 27; 23(1):22-8. PubMed ID: 19751843
    [Abstract] [Full Text] [Related]

  • 11. A novel ELR-CXC chemokine antagonist reduces intestinal ischemia reperfusion-induced mortality, and local and remote organ injury.
    Zhao X, Town JR, Yang A, Zhang X, Paur N, Sawicki G, Gordon JR.
    J Surg Res; 2010 Aug 27; 162(2):264-73. PubMed ID: 19691980
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks lung inflammation in swine barn dust-instilled mice.
    Schneberger D, Gordon JR, DeVasure JM, Boten JA, Heires AJ, Romberger DJ, Wyatt TA.
    Pulm Pharmacol Ther; 2015 Apr 27; 31():55-62. PubMed ID: 25681618
    [Abstract] [Full Text] [Related]

  • 14. Combined CXCR1/CXCR2 antagonism decreases radiation-induced alveolitis in the mouse.
    Fox J, Gordon JR, Haston CK.
    Radiat Res; 2011 May 27; 175(5):657-64. PubMed ID: 21342009
    [Abstract] [Full Text] [Related]

  • 15. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
    Liu X, Peng J, Sun W, Yang S, Deng G, Li F, Cheng JW, Gordon JR.
    Tohoku J Exp Med; 2012 Oct 27; 228(2):147-56. PubMed ID: 23019013
    [Abstract] [Full Text] [Related]

  • 16. CXCR1/CXCR2 antagonist G31P inhibits nephritis in a mouse model of uric acid nephropathy.
    Ye Y, Zhang Y, Wang B, Walana W, Wei J, Gordon JR, Li F.
    Biomed Pharmacother; 2018 Nov 27; 107():1142-1150. PubMed ID: 30257327
    [Abstract] [Full Text] [Related]

  • 17. The antagonist of CXCR1 and CXCR2 protects db/db mice from metabolic diseases through modulating inflammation.
    Cui S, Qiao L, Yu S, Men L, Li Y, Li F, Du J.
    Am J Physiol Endocrinol Metab; 2019 Dec 01; 317(6):E1205-E1217. PubMed ID: 31573846
    [Abstract] [Full Text] [Related]

  • 18. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
    Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D.
    Int Immunopharmacol; 2012 Jul 01; 13(3):225-31. PubMed ID: 22561413
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
    Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Mårdh CK.
    J Pharmacol Exp Ther; 2015 May 01; 353(2):340-50. PubMed ID: 25736418
    [Abstract] [Full Text] [Related]

  • 20. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
    Catusse J, Struyf S, Wuyts A, Weyler M, Loos T, Gijsbers K, Gouwy M, Proost P, Van Damme J.
    Biochem Pharmacol; 2004 Nov 15; 68(10):1947-55. PubMed ID: 15476666
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.